LexaGene Talking to Major Players in Plague Detection
CEO Dr. Jack Regan joined Steve Darling from Proactive Investors to share news the company will be approaching Government and showing the effectiveness and speed of their MiQLab in detecting plague.
Read Dr Jack Regan on Pandemic Prevention with Better Diagnostics
Writing in Clinical Lab Products Magazine, Dr Jack Regan makes a strong case that diagnostic technology investment is key to preventing future pandemic diseases: Diagnostics is an area that has been largely underfunded, despite the repeated and consistent warnings from virologists, microbiologists, epidemiologists, and other public health stakeholders. Years of underfunding diagnostics and inadequate testing…
Proactive Investors on MiQLab Sale to Alpine Veterinary Hospital
Check out Proactive Investors’ coverage of LexaGene’s contract with Alpine Veterinary Hospital – and Dr Regan’s upcoming conference appearances:
LexaGene’s MiQLab to be a Game Changer for Veterinary Care
LexaGene’s MiQLab to be a Game Changer for Veterinary Care: Read article by Benzinga describing how LexaGene has built MiQLab, a new molecular diagnostics analyzer that can do in-clinic veterinary diagnostic testing at the point-of-care.
BioWorld Covergage LexaGene
LexaGene covered in BioWorld on the MiQLab’s ability to detect new variants of pathogens at point-of-care. Read more.
Rapid POC Diagnostics in Vet Medicine
Dr. Sam Stewart, DVM from Ethos, describes the benefits of rapid POC diagnostics in veterinary medicine. Ethos will implement LexaGene‘s MiQLab to help deliver innovative evidence-based patient care. The article is from fall IVC Journal vol. 10 issue 4. Read now.
BioSpace Coverage on LexaGene EUA Studies
Read BioSpace’s recent coverage of LexaGene’s plans to submit for FDA Emergency Use Authorization, and how the MiQLab™ system is ideally suited to test for COVID-19 variants at point-of-care. More.
Outbreak News Today coverage of EUA plans
LexaGene was recently covered by Outbreak News Today on the news that LexaGene will begin in-house testing for variants of COVID-19. Read the story here.
LexaGene featured by Medical Technology
LexaGene’s new automated testing platform: Massachusetts-based LexaGene is preparing to launch MiQLab, the company’s flagship product, which provides automated pathogen testing in one platform.
Article on Penn Vet and MiQLab
American Animal Hospital Association (AAHA)’s NEWStat publication reviews LexaGene’s MiQLab system in a recent feature. Dr. Shelley Rankin of Penn Vet discusses the recent placement of a MiQLab under LexaGene’s Early Access Program.
COVID Q&A with Infection Control Today
Dr. Jack Regan, LexaGene’s CEO gives his perspective on fighting COVID-19 with better diagnostics and automated PCR testing.
LexaGene mentioned in Future Lab
LexaGene mentioned in Trends in COVID-19 Testing: Diagnostics and Serological, on Future Lab by Biocompare